<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35497489</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>12</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2772-7246</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>3</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Drug and alcohol dependence reports</Title>
          <ISOAbbreviation>Drug Alcohol Depend Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Impact of reduced restrictions on buprenorphine prescribing during COVID-19 among patients in a community-based treatment program.</ArticleTitle>
        <Pagination>
          <StartPage>100055</StartPage>
          <MedlinePgn>100055</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.dadr.2022.100055</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Medications such as buprenorphine are considered the gold standard for the treatment of opioid use disorders. This study aimed to determine whether less restrictive buprenorphine prescribing practices during the COVID-19 pandemic impacted retention in and adherence to buprenorphine among patients accessing treatment from 2018-2020 at a community-based syringe services program.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="UNASSIGNED">In this retrospective cohort study, we compared retention in treatment before and during the COVID-19 pandemic. Then, with relaxed restrictions acting as the intervention in a natural experiment, we conducted a sub-analysis of "continuity participants" who accessed treatment services both before and during the COVID-19 period. Records of 418 historical control patients treated with buprenorphine before COVID-19 were compared to 88 patients enrolled during COVID-19 (n=43 remote telemedicine and n=45 remote provider with patient on-site). Cox proportional hazards regressions were used to assess risk factors for treatment discontinuation. The sub-analysis used proportion of days covered (PDC) differences before and during COVID-19 (n=164) for a paired analysis in a nonparametric bootstrap test.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The risk of discontinuation was 71% lower in those accessing remote telemedicine during COVID-19 (HR=0.29; CI: 0.18, 0.47) and 51% lower in those accessing their remote provider onsite during COVID-19 (HR=0.49; CI:0.31, 0.77), compared to the historical control group. The average PDC did not significantly differ before and during COVID-19 (difference=2.4%; CI:-0.6%, 5.3%).</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">The risk of discontinuing treatment was lower in both COVID-19 treatment groups compared to historical controls. Less restrictive buprenorphine prescribing guidelines during COVID-19 led to improved retention in care over 6-months.</AbstractText>
          <CopyrightInformation>© 2022 The Authors. Published by Elsevier B.V.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ward</LastName>
            <ForeName>Kathleen M</ForeName>
            <Initials>KM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Community Health and Prevention, Dornsife School of Public Health, Drexel University, Philadelphia, PA, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Scheim</LastName>
            <ForeName>Ayden</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, PA, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Jonathan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Biology, Princeton University, Princeton, NJ, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cocchiaro</LastName>
            <ForeName>Benjamin</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Prevention Point Philadelphia, Philadelphia, PA, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Singley</LastName>
            <ForeName>Katie</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Community Health and Prevention, Dornsife School of Public Health, Drexel University, Philadelphia, PA, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Roth</LastName>
            <ForeName>Alexis M</ForeName>
            <Initials>AM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Community Health and Prevention, Dornsife School of Public Health, Drexel University, Philadelphia, PA, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>26</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Drug Alcohol Depend Rep</MedlineTA>
        <NlmUniqueID>9918350383506676</NlmUniqueID>
        <ISSNLinking>2772-7246</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Adherence</Keyword>
        <Keyword MajorTopicYN="N">Buprenorphine</Keyword>
        <Keyword MajorTopicYN="N">COVID-19</Keyword>
        <Keyword MajorTopicYN="N">Opioid use disorder</Keyword>
        <Keyword MajorTopicYN="N">People who use drugs</Keyword>
        <Keyword MajorTopicYN="N">Retention</Keyword>
        <Keyword MajorTopicYN="N">Telemedicine</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>2</Day>
          <Hour>7</Hour>
          <Minute>2</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35497489</ArticleId>
        <ArticleId IdType="pmc">PMC9040407</ArticleId>
        <ArticleId IdType="doi">10.1016/j.dadr.2022.100055</ArticleId>
        <ArticleId IdType="pii">S2772-7246(22)00033-6</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>American Society of Addiction Medicine, 2020. ASAM COVID-19 task force recommendations: caring for patients during the COVID-19 pandemic adjusting drug testing protocols.</Citation>
        </Reference>
        <Reference>
          <Citation>Andrade S.E., Kahler K.H., Frech F., Chan K.A. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol. Drug Saf. 2006;15(8):565–574.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16514590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bachhuber M.A., Thompson C., Prybylowski A., Benitez J., Mazzella S., Barclay D. Description and outcomes of a buprenorphine maintenance treatment program integrated within Prevention Point Philadelphia, an urban syringe exchange program. Subst. Abus. 2018;39:167–172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29474119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benner J.S., Glynn R.J., Mogun H., Neumann P.J., Weinstein M.C., Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455–461.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12132975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bokolo Anthony J. Use of telemedicine and virtual care for remote treatment in response to COVID-19 pandemic. J. Med. Syst. 2020;44(7):132.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7294764</ArticleId>
            <ArticleId IdType="pubmed">32542571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chai P.R., Castillo-Mancilla J., Buffkin E., Darling C., Rosen R.K., Horvath K.J., Boudreaux E.D., Robbins G.K., Hibberd P.L., Boyer E.W. Utilizing an ingestible biosensor to assess real-time medication adherence. J. Med. Toxicol. 2015;11(4):439–444.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4675608</ArticleId>
            <ArticleId IdType="pubmed">26245878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chalasani R., Shinabery J.M., Goetz C.T., Chang C.-C.H., Yang Q., Suda K.J., Gellad W.F. Buprenorphine dispensing in Pennsylvania during the COVID-19 pandemic, January to October 2020. J. Gen. Intern. Med. 2021;36(12):3915–3917.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8354093</ArticleId>
            <ArticleId IdType="pubmed">34378112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cunningham C.O., Giovanniello A., Kunins H.V., Roose R.J., Fox A.D., Sohler N.L. Buprenorphine treatment outcomes among opioid-dependent cocaine users and non-users. Am. J. Addict. 2013;22(4):352–357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3694744</ArticleId>
            <ArticleId IdType="pubmed">23795874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedman J., Akre S. COVID-19 and the drug overdose crisis: uncovering the deadliest months in the United States, January‒July 2020. Am. J. Public Health. 2021;111(7):1284–1291.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8493145</ArticleId>
            <ArticleId IdType="pubmed">33856885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedman J., Montero F., Bourgois P., Wahbi R., Dye D., Goodman-Meza D., Shover C. Xylazine spreads across the US: a growing component of the increasingly synthetic and polysubstance overdose crisis. Drug Alcohol Depend. 2022;233</Citation>
        </Reference>
        <Reference>
          <Citation>Gilmore A.K., Wilson S.M., Skopp N.A., Osenbach J.E., Reger G. A systematic review of technology-based interventions for co-occurring substance use and trauma symptoms. J. Telemed. Telecare. 2017;23(8):701–709.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27534823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grambsch P.M., Therneau T.M. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81(3):515–526.</Citation>
        </Reference>
        <Reference>
          <Citation>Gryczynski J., Mitchell S.G., Jaffe J.H., O’Grady K.E., Olsen Y.K., Schwartz R.P. Leaving buprenorphine treatment: patients’ reasons for cessation of care. J. Subst. Abuse Treat. 2014;46(3):356–361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3947058</ArticleId>
            <ArticleId IdType="pubmed">24238714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harris M., Johnson S., Mackin S., Saitz R., Walley A.Y., Taylor J.L. Low barrier tele-buprenorphine in the time of COVID-19: a case report. J. Addict. Med. 2020;14(4):e136–e138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7273942</ArticleId>
            <ArticleId IdType="pubmed">32433364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hodder S.L., Feinberg J., Strathdee S.A., Shoptaw S., Altice F.L., Ortenzio L., Beyrer C. The opioid crisis and HIV in the USA: deadly synergies. Lancet. 2021;397(10279):1139–1150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33617769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holtzman D., Asher A.K., Schillie S. The changing epidemiology of hepatitis C virus infection in the United States during the years 2010 to 2018. Am. J. Public Health. 2021;111(5):949–955.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8034015</ArticleId>
            <ArticleId IdType="pubmed">33734844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoots B., Vivolo-Kantor A., Seth P. The rise in non-fatal and fatal overdoses involving stimulants with and without opioids in the United States. Addiction. 2020;115(5):946–958.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31912625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Humphry J. Digital First’: homelessness and data use in an online service environment. Commun. Res. Pract. 2019;5(2):172–187.</Citation>
        </Reference>
        <Reference>
          <Citation>Iheanacho T., Payne K., Tsai J. Mobile, community-based buprenorphine treatment for veterans experiencing homelessness with opioid use disorder: a pilot, feasibility study. Am. J. Addict. 2020;29(6):485–491.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32367557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khatri U.G., Aronowitz S.V. Considering the harms of our habits: the reflexive urine drug screen in opioid use disorder treatment. J. Subst. Abuse Treat. 2021;123</Citation>
        </Reference>
        <Reference>
          <Citation>Krawczyk N., Buresh M., Gordon M.S., Blue T.R., Fingerhood M.I., Agus D. Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: addressing a critical care gap. J. Subst. Abuse Treat. 2019;103:1–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6612429</ArticleId>
            <ArticleId IdType="pubmed">31229187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larochelle M.R., Bernson D., Land T., Stopka T.J., Wang N., Xuan Z., Bagley S.M., Liebschutz J.M., Walley A.Y. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann. Intern. Med. 2018;169(3):137–145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6387681</ArticleId>
            <ArticleId IdType="pubmed">29913516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu S., O’Donnell J., Gladden R.M., McGlone L., Chowdhury F. Trends in nonfatal and fatal overdoses involving benzodiazepines - 38 States and the District of Columbia, 2019-2020. MMWR Morb. Mortal Wkly. Rep. 2021;70(34):1136–1141.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8389388</ArticleId>
            <ArticleId IdType="pubmed">34437522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nordeck C.D., Buresh M., Krawczyk N., Fingerhood M., Agus D. Adapting a low-threshold buprenorphine program for vulnerable populations during the COVID-19 pandemic. J. Addict. Med. 2021;15(5):364–369.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8489578</ArticleId>
            <ArticleId IdType="pubmed">33177436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nouri S., Khoong E.C., Lyles C.R., Karliner L. Addressing equity in telemedicine for chronic disease management during the Covid-19 pandemic. NEJM Catal. Innov. Care Deliv. 2020;1(3)</Citation>
        </Reference>
        <Reference>
          <Citation>Olfson M., Zhang V., Schoenbaum M., King M. Trends in buprenorphine treatment in the United States, 2009-2018. JAMA. 2020;323(3):276–277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6990679</ArticleId>
            <ArticleId IdType="pubmed">31961408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ortega G., Rodriguez J.A., Maurer L.R., Witt E.E., Perez N., Reich A., Bates D.W. Telemedicine, COVID-19, and disparities: policy implications. Health Policy Technol. 2020;9(3):368–371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7428456</ArticleId>
            <ArticleId IdType="pubmed">32837888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Payne B.E., Klein J.W., Simon C.B., James J.R., Jackson S.L., Merrill J.O., Zhuang R., Tsui J.I. Effect of lowering initiation thresholds in a primary care-based buprenorphine treatment program. Drug Alcohol Depend. 2019;200:71–77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31103879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Powell D., Alpert A., Pacula R.L. A transitioning epidemic: how the opioid crisis is driving the rise in hepatitis C. Health Aff. 2019;38(2):287–294.</Citation>
        </Reference>
        <Reference>
          <Citation>Santo T., Jr, Clark B., Hickman M., Grebely J., Campbell G., Sordo L., Chen A., Tran L.T., Bharat C., Padmanathan P., Cousins G., Dupouy J., Kelty E., Muga R., Nosyk B., Min J., Pavarin R., Farrell M., Degenhardt L. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis. JAMA Psychiatry. 2021;78(9):979–993.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8173472</ArticleId>
            <ArticleId IdType="pubmed">34076676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stringer K.L., Langdon K.J., McKenzie M., Brockmann B., Marotta P. Leveraging COVID-19 to sustain regulatory flexibility in the treatment of opioid use disorder. J. Subst. Abuse Treat. 2021;123</Citation>
        </Reference>
        <Reference>
          <Citation>Substance Abuse and Mental Health Services Administration  . Results from the 2019 National Survey on Drug Use and Health; Rockville, MD: 2020. Key Substance Use and Mental Health Indicators in the United States.</Citation>
        </Reference>
        <Reference>
          <Citation>Substance Abuse and Mental Health Services Administration, 2020b. Medications for opioid use disorder, Treatment Improvement Protocol (TIP) Series 63. Rockville, MD.</Citation>
        </Reference>
        <Reference>
          <Citation>Tofighi B., McNeely J., Walzer D., Fansiwala K., Demner A., Chaudhury C.S., Subudhi I., Schatz D., Reed T., Krawczyk N. A telemedicine buprenorphine clinic to serve New York city: initial evaluation of the NYC public hospital system's initiative to expand treatment access during the COVID-19 pandemic. J. Addict. Med. 2021;16(1):e40.</Citation>
        </Reference>
        <Reference>
          <Citation>U.S. Department of Justice Drug Enforcement Administration, 2021. Diversion control division COVID-19 information page | telemedicine DEA policy. https://www.deadiversion.usdoj.gov/coronavirus.html. (Accessed July 14 2021).</Citation>
        </Reference>
        <Reference>
          <Citation>Wang L., Weiss J., Ryan E.B., Waldman J., Rubin S., Griffin J.L. Telemedicine increases access to buprenorphine initiation during the COVID-19 pandemic. J. Subst. Abuse Treat. 2021;124</Citation>
        </Reference>
        <Reference>
          <Citation>Weinstein L.C., Iqbal Q., Cunningham A., Debates R., Landistratis G., Doggett P., Silverio A. Retention of patients with multiple vulnerabilities in a federally qualified health center buprenorphine program: Pennsylvania, 2017–2018. Am. J. Public Health. 2020;110(4):580–586.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7067078</ArticleId>
            <ArticleId IdType="pubmed">32078355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weintraub E., Greenblatt A.D., Chang J., Himelhoch S., Welsh C. Expanding access to buprenorphine treatment in rural areas with the use of telemedicine. Am. J. Addict. 2018;27(8):612–617.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30265425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Williams A.R., Nunes E.V., Bisaga A., Levin F.R., Olfson M. Development of a cascade of care for responding to the opioid epidemic. Am. J. Drug Alcohol Abuse. 2019;45(1):1–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6404749</ArticleId>
            <ArticleId IdType="pubmed">30675818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhai Y. A call for addressing barriers to telemedicine: health disparities during the COVID-19 pandemic. Psychother. Psychosom. 2021;90(1):64–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7316653</ArticleId>
            <ArticleId IdType="pubmed">32498070</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
